Research programme: mRNA vaccines - Altamira Therapeutics/Univercells
Latest Information Update: 18 Aug 2024
At a glance
- Originator Altamira Therapeutics; Univercells
- Class RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 10 Aug 2024 Early research in Unspecified (Prevention) in France (unspecified route) (Altamira Therapeutics pipeline; August 2024)
- 10 Aug 2024 Early research in Unspecified (Prevention) in Spain (unspecified route) (Altamira Therapeutics pipeline; August 2024)
- 25 Mar 2024 Altamira Therapeutics and Univercells collaborates for the development of nanoparticle-delivered mRNA vaccines